mapigroup.comICON plc | Clinical Research Organisation (CRO) for Drug Development

Toggle navigation Services Services Our services span the entire lifecycle of product development and commercialisation, and can be adapted to suit small local trials or large global programs. Read More Services Adaptive Trials Clinical Research Services Consulting Early Phase Functional Services Provision Laboratories Language Services Medical Imaging Real World Intelligence Site & Patient Solutions Value Access Outcomes COVID-19 clinical operations Clinical trials during COVID-19. Decentralised & hybrid clinical solutions Bringing the clinical trial to the patient with innovation and in-home solutions. Sectors Sectors ICON provides its full range of clinical, consulting and commercial services across several industry sectors. Read More Sectors Biosimilars Biotech Government & Public Health Solutions Medical Device Pharmaceuticals The IVDR journey A roadmap to meet 2022 deadlines, while navigating pandemic disruptions. Government and Public Health Solutions Serving governments, multinational public health organisations, and global NGOs. Therapeutics Therapeutics We have extensive experience in a broad range of therapeutic areas. Managing studies in all major geographies, we have established solid working relationships with the world’s leading investigators. Read More Therapeutics Cardiovascular Cell and Gene Therapies Central Nervous System Endocrine & Metabolic Disorders Infectious Diseases Internal Medicine & Immunology Medical Device Oncology Rare & Orphan Diseases Transplant Immunology Women’s Health Vaccines ICON has recently led the development of 17 vaccines resulting in FDA/EMA approvals. We are currently working on a number of COVID-19 vaccine trials. Therapeutics insights ICON’s therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more. Innovation Innovation We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs. Read More Innovation FIRECREST Safety Reporting Solution One Search Evidence Platform FLEX ADVANTAGE Medical Imaging Technology NONMEM ICONIK PDx-POP PubsHub SIMS FIRECREST With travel restrictions due to COVID-19, FIRECREST helps deliver and manage remote training for investigators. Patient Engagement Platform Connecting patients with the right trial in the right location. Insights Insights BioPharma companies and Medical Devices manufacturers face growing operational, regulatory and economic challenges. ICON provides analysis and key insights on these challenges, with practical advice and recommendations. Read More Insights Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel Coronavirus Observatory Aggregated news on COVID-19 clinical trials. Decentralised & hybrid clinical trials Patient focused research for better outcomes. News & Events News & Events ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards. Read More News & Events Press Releases In the News Mediakit Awards Events Webinars Social Media Webinar: HIV treatments from antiretroviral therapy to vaccines 3 March, 2021 ICON supports Pfizer and BioNTech on COVID-19 vaccine trial Trial capabilities key to enabling agility and speed in global study involving 44,000 subjects. About ICON About ICON Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life. Read More About ICON Company History ICON in Asia Pacific ICON in Latin America Leadership Quality Environmental, Social & Governance ICON is committed to making a positive impact on our people, environment and our community. ICON and You Partners making a difference. Careers Investors Investigators Patients Contact EN | 日本語 Cell and Gene Therapy clinical trials The promise and complexity of living therapies Read the eBook The evolution of HIV treatments From antiretroviral therapy to vaccines, where we are today and what’s next Read the whitepaper The IVDR journey A roadmap to meet 2022 deadlines, while navigating pandemic disruptions Read the whitepaper Agile Clinical Monitoring The flexibility to keep your trials on track Read the whitepaper Traumatic brain injury clinical trials From identifying biomarkers to improving clinical trial efficiency. ICER’s impact on payer decision making Results of ICON’s third annual survey. Mitigating the impact of COVID-19 on cardiovascular trials Ensure patient safety and trial integrity during a global pandemic. Dynamics of patient centricity in clinical research Exploring the patient dynamic from different perspectives. Webinars Upcoming webinar: HIV treatments from antiretroviral therapy to vaccines 3 March, 2021. Register now. On-demand webinar: Engaging Physicians to support and increase clinical research activity Making it more attractive and easier for healthcare professionals to consider clinical trials. On-demand webinars Visit our webinar channel to access other recent webinars. Featured Services COVID-19 clinical operations Keeping your clinical trial on track in an evolving environment. Site & Patient Solutions Transforming recruitment through patient-centric trials and real-world, real-time data. Biotech ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation. Functional Resourcing From recruitment of a single clinical professional to managing entire global functions. Biosimilars ICON can support product design, development and registration, regulatory support and commercialisation of Biosimilars. Increasing Site and Patient Compliance FIRECREST: Digital solutions to increase efficiency in clinical trials by driving site performance. ICON Insights 09 February 2021 mRNA vaccines from COVID-19 to HIV How one virus accelerated vaccine research, spurring innovation and hope for a cure in another Read more 05 February 2021 Executing under pressure: Developing a strategy for high risk devices under IVDR Manufacturers who have not begun preparations will need to adopt a strategy to address gaps in meeting the new regulation. Read more 03 February 2021 The Importance of partnering for bioanalytical studies Bioanalytical studies are an important aspect of biologic drug development that may necessitate partnering with bioanalysis experts. Read more 26 January 2021 Clinical Evidence under IVDR - how much is enough? The new In Vitro Diagnostic Regulation (IVDR) aims to harmonise regulatory framework across the European Union (EU) to ensure the safety and performance of devices by placing greater responsibility on manufacturers to demonstrate that their products meet stringent requirements. Read more 18 January 2021 Data capture: The benefits and evolution of eCOA As the demand for improving patient safety in clinical trials continues to rise, so will the use of technology as a way to better capture data and enhance clinical outcome assessments (COAs). Read more 12 January 2021 Risk, vigilance, and remediation under IVDR The In Vitro Diagnostics Regulation (IVDR) — which goes into effect on May 26, 2022 — will have a lasting impact on the entire in vitro diagnostics (IVD) lifecycle, from development through clinical investigations and regulatory approval. Read more 08 January 2021 Managing COVID disruptions within IVDR timelines The COVID-19 pandemic has greatly impacted the IVD industry, including travel and social distancing restrictions, creating hassles and stalling NB designation processes. Read more 06 January 2021 Exploring the benefits of biotech partnerships The biotechnology sector is leading the way in developing innovative therapies that will address the unmet needs...